203 related articles for article (PubMed ID: 37480275)
21. Appraisal of Novel Oncological Therapies by the Scottish Medicines Consortium and the National Institute for Health and Care Excellence: A Comparative Study of Six Years of Data.
Taylor R
Cureus; 2023 Dec; 15(12):e50560. PubMed ID: 38222244
[TBL] [Abstract][Full Text] [Related]
22. The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs.
Vreman RA; Bloem LT; van Oirschot S; Hoekman J; van der Elst ME; Leufkens HG; Klungel OH; Goettsch WG; Mantel-Teeuwisse AK
Int J Health Policy Manag; 2022 May; 11(5):642-650. PubMed ID: 33131224
[TBL] [Abstract][Full Text] [Related]
23. The Challenge for Orphan Drugs Remains: Three Case Studies Demonstrating the Impact of Changes to NICE Methods and Processes and Alternative Mechanisms to Value Orphan Products.
Lee D; McCarthy G; Saeed O; Allen R; Malottki K; Chandler F
Pharmacoecon Open; 2023 Mar; 7(2):175-187. PubMed ID: 36315388
[TBL] [Abstract][Full Text] [Related]
24. Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries.
Kleijnen S; Lipska I; Leonardo Alves T; Meijboom K; Elsada A; Vervölgyi V; d'Andon A; Timoney A; Leufkens HG; De Boer A; Goettsch WG
Ann Oncol; 2016 Sep; 27(9):1768-75. PubMed ID: 27329251
[TBL] [Abstract][Full Text] [Related]
25. Methods for the comparative evaluation of pharmaceuticals.
Zentner A; Velasco-Garrido M; Busse R
GMS Health Technol Assess; 2005 Nov; 1():Doc09. PubMed ID: 21289930
[TBL] [Abstract][Full Text] [Related]
26. Is the National Institute for Health and Care Excellence (NICE) in England more 'innovation-friendly' than the Federal Joint Committee (G-BA) in Germany?
Schaefer R; Schlander M
Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):453-462. PubMed ID: 30556745
[No Abstract] [Full Text] [Related]
27. A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer.
Jäkel A; Plested M; Dharamshi K; Modha R; Bridge S; Johns A
Appl Health Econ Health Policy; 2013 Feb; 11(1):27-43. PubMed ID: 23329379
[TBL] [Abstract][Full Text] [Related]
28. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
29. Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies.
Makady A; Ham RT; de Boer A; Hillege H; Klungel O; Goettsch W;
Value Health; 2017 Apr; 20(4):520-532. PubMed ID: 28407993
[TBL] [Abstract][Full Text] [Related]
30. Exploring uncertainty and use of real-world data in the National Institute for Health and Care Excellence single technology appraisals of targeted cancer therapy.
Kang J; Cairns J
BMC Cancer; 2022 Dec; 22(1):1268. PubMed ID: 36471259
[TBL] [Abstract][Full Text] [Related]
31. Oncology drugs and added benefit: insights from 3 European health technology assessment agencies on the role of efficacy endpoints.
Smith N; Fu AC; Fisher T; Meletiche D; Pawar V
J Med Econ; 2022; 25(1):1-6. PubMed ID: 34809504
[TBL] [Abstract][Full Text] [Related]
32. Justice, Transparency and the Guiding Principles of the UK's National Institute for Health and Care Excellence.
Charlton V
Health Care Anal; 2022 Jun; 30(2):115-145. PubMed ID: 34750743
[TBL] [Abstract][Full Text] [Related]
33. Differences in cancer drug assessment between Spain and the United Kingdom.
Lozano-Blázquez A; Dickson R; Fraga-Fuentes MD; Martínez-Martínez F; Calleja-Hernández MÁ
Eur J Cancer; 2015 Sep; 51(13):1843-52. PubMed ID: 26119375
[TBL] [Abstract][Full Text] [Related]
34. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
Williams I; Bryan S; McIver S
J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
[TBL] [Abstract][Full Text] [Related]
35. Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice Variations.
Vreman RA; Mantel-Teeuwisse AK; Hövels AM; Leufkens HGM; Goettsch WG
Value Health; 2020 Jan; 23(1):10-16. PubMed ID: 31952664
[TBL] [Abstract][Full Text] [Related]
36. Mapping Health Technology Assessment Agency Approaches for Biosimilar Value Assessment: An ISPOR Special Interest Group Report.
Barcina Lacosta T; Inotai A; Pereira CL; Barbier L; Simoens S
Value Health; 2024 May; 27(5):543-551. PubMed ID: 38702140
[TBL] [Abstract][Full Text] [Related]
37. HTA decision-making for drugs for rare diseases: comparison of processes across countries.
Stafinski T; Glennie J; Young A; Menon D
Orphanet J Rare Dis; 2022 Jul; 17(1):258. PubMed ID: 35804398
[TBL] [Abstract][Full Text] [Related]
38. Do different clinical evidence bases lead to discordant health-technology assessment decisions? An in-depth case series across three jurisdictions.
Spinner DS; Birt J; Walter JW; Bowman L; Mauskopf J; Drummond MF; Copley-Merriman C
Clinicoecon Outcomes Res; 2013; 5():69-85. PubMed ID: 23403392
[TBL] [Abstract][Full Text] [Related]
39. [Haute Autorite de sante opinion on cost-effectiveness of health products : results and perspectives].
Midy F; Raimond V; Thébaut C; Sambuc C; Rumeau-Pichon C
Sante Publique; 2015; 27(5):691-700. PubMed ID: 26752035
[TBL] [Abstract][Full Text] [Related]
40. Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia.
Fischer KE; Heisser T; Stargardt T
Health Policy; 2016 Oct; 120(10):1115-1122. PubMed ID: 27628196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]